Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
about
Effects of PHA-665752 and vemurafenib combination treatment on in vitro and murine xenograft growth of human colorectal cancer cells with BRAFV600E mutations.A somatic mutation of RasGRP3 decreases Na/I symporter expression in metastases of radioactive iodine-refractory thyroid cancer by stimulating the Akt signaling pathway
P2860
Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Acquired resistance to BRAF in ...... c-Met-mediated AKT activation.
@en
Acquired resistance to BRAF in ...... mesenchymal transition in BRAF
@nl
type
label
Acquired resistance to BRAF in ...... c-Met-mediated AKT activation.
@en
Acquired resistance to BRAF in ...... mesenchymal transition in BRAF
@nl
prefLabel
Acquired resistance to BRAF in ...... c-Met-mediated AKT activation.
@en
Acquired resistance to BRAF in ...... mesenchymal transition in BRAF
@nl
P2093
P2860
P356
P1433
P1476
Acquired resistance to BRAF in ...... c-Met-mediated AKT activation
@en
P2093
Chang-Hoon Kim
Da Hee Kim
Eun Chang Choi
Hwi Jung Na
Hyung Kwon Byeon
Jae Wook Kim
Jaemoon Yang
Ji-Hoon Kim
Joo-Heon Yoon
Jung Min Kim
P2860
P304
P356
10.18632/ONCOTARGET.13480
P407
P577
2017-01-01T00:00:00Z